The Recall Desk
SevereFDA (Drugs)·D-0805-2021·Announced 2021-09-22

AMINOSYN II 15% Amino Acid Injection Recalled for Particulate Matter

ICU Medical Inc is recalling AMINOSYN II 15% An Amino Acid Injection due to the presence of particulate matter including fibers, hair, and proteinaceous material found in retained samples.

What this means for you

Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.

Our severity reasoning: The FDA classified this recall as Class I. According to the severity rubric, FDA Class I recalls receive a minimum score of 4 (Severe), regardless of whether illnesses or injuries have been reported.

Plain-English summary

ICU Medical Inc is recalling AMINOSYN II 15% An Amino Acid Injection, Sulfite-Free, 2000 mL in flexible containers (NDC 0409-7171-17, Lot 4989094, Expiration 01-APR-2022) because particulate matter has been identified in the product. The particulate matter consists of fibers, hair, proteinaceous material, and other particles.

This product was distributed nationwide in the USA. AMINOSYN II 15% is a prescription amino acid injection used in medical settings.

Consumers and healthcare providers who have received this product should not use it. Any remaining units of the affected lot should be quarantined and not administered to patients. Healthcare facilities should contact their supplier or ICU Medical Inc for instructions on returning the product or obtaining replacement units.

The recalled product

Product
AMINOSYN II 15% An Amino Acid Injection, Sulfite-Free, 2000 mL in flexible containers, Rx ONLY, Hospira, Inc., Lake Forest, IL 60045. NDC 0409-7171-17
Manufacturer
ICU Medical Inc
Hazard
  • particulate-matter
  • fibers
  • contamination

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (1)

  • Lot: 4989094 Exp. 01-APR-2022

Distribution

Distributed nationwide across the United States.